We have developed several compounds capable of targeting specific cells within the body. These could be combined with anticancer drugs for the treatment of Myelofibrosis .
Treatment of blood diseases
Myelofibrosis (MF) is a serious blood disease where the average patient survival is five years. Currently there are no effective treatments available, only temporary relief for symptoms such as enlargement of the spleen and liver.
Stem cell transplantation remains the most common treatment for MF but is expensive and risky.
The market for MF drugs is growing, estimated to reach US $2.8 billion dollars by 2020.
Paving the way for cancer sufferers
There is a fast growing need for effective drug treatments that tackle blood related cancers at the root of the problem, rather than merely relief of symptoms.
Our teams have been studying thrombopoietin (TPO) an important signalling protein found in bone marrow that affects processes with the formation of healthy blood cells. In particular, TPO controls the production of megakaryocytes, cells that generate platelets required to control clotting.
We have identified TPO receptors as a potentially important and novel drug target for treating myeloproliferative growths.
A library of compounds
We have developed a library of patented compounds capable of targeting these TPO receptors, which in turn can be combined with anticancer drugs.
These molecules also have potential to be used prior to patient marrow/haematopoietic stem cell (HSC) transplantation, reducing side effects compared to traditional treatment options.
We are seeking pharmaceutical and Venture Capital partners to help us continue this important fight.
Do business with us to help your organisation thrive
We partner with small and large companies, government and industry in Australia and around the world.